{
  "Variants Include": [
    {
      "Gene": "SLC22A1",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.46K> (p.Cys46Thr)",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "K",
            "position": "46"
          },
          "Protein Change": {
            "ref": "Cys",
            "alt": "Thr",
            "position": "46"
          },
          "Description in input context": "E46K mutation (p.Cys46Thr)"
        },
        {
          "HGVS": "NM_001126112.3:c.30P> (p.Gln30Pro)",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "P",
            "position": "30"
          },
          "Protein Change": {
            "ref": "Gln",
            "alt": "Pro",
            "position": "30"
          },
          "Description in input context": "A30P mutation (p.Gln30Pro)"
        },
        {
          "HGVS": "NM_001126112.3:c.53T> (p Tyr53 Cys)",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "T",
            "position": "53"
          },
          "Protein Change": {
            "ref": "Tyr",
            "alt": "Cys",
            "position": "53"
          },
          "Description in input context": "A53T mutation (p Tyr53 Cys)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Lewy Body Disease",
    "MONDO": "MONDO:0019257"
  },
  "Experiment Method": [
    {
      "Assay Method": "Thioflavin S Assay",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293",
        "Description": "The experiment was conducted using the HEK293 cell line."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.46K> (p.Cys46Thr)",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Partial loss-of-function",
          "Result Description": "αS aggregation increased by 50% for the E46K mutation."
        },
        {
          "Variant": "NM_001126112.3:c.30P> (p.Gln30Pro)",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Partial loss-of-function",
          "Result Description": "αS aggregation increased by 30% for the A30P mutation."
        },
        {
          "Variant": "NM_001126112.3:c.53T> (p Tyr53 Cys)",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Partial loss-of-function",
          "Result Description": "αS aggregation increased by 40% for the A53T mutation."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Thioflavin S was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "No",
        "Description": "No negative controls were mentioned in the literature."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "αS aggregation less than 30% on day 7.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "αS aggregation greater than 50% on day 7.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}